RCA
CLRB icon

Riverview Capital Advisers’s Cellectar Biosciences CLRB Stock Holding History

Riverview Capital Advisers’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.1K Hold
10,384
– – 0.01% 87
2026
Q1 		$50.1K Hold
10,384
– – 0.02% 85
2025
Q4 		$50.1K Hold
10,384
– – 0.02% 90
2025
Q3 		$50.1K Sell
10,384
-116
-1% -$575 0.01% 96
2025
Q2 		$74.7K Buy
+10,500
New +$91.9K 0.02% 93

Other funds holding CLRB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Riverview Capital Advisers's CLRB Position: Q2 2026 in Review

Riverview Capital Advisers held its Cellectar Biosciences (CLRB) position steady in Q2 2026 at 10,384 shares worth $50.1K. The position accounts for 0.01% of the portfolio, ranked #87.

Riverview Capital Advisers first reported a position in CLRB in Q2 2025 and has held it in 5 quarters since. The position peaked at $74.7K in Q2 2025. 18 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Riverview Capital Advisers held 10,384 shares of Cellectar Biosciences worth $50.1K as of Q2 2026.
  • Riverview Capital Advisers left its Cellectar Biosciences share count unchanged in Q2 2026.
  • Cellectar Biosciences made up 0.01% of Riverview Capital Advisers's portfolio in Q2 2026, its #87 holding.
  • Riverview Capital Advisers first reported a position in Cellectar Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Riverview Capital Advisers's Cellectar Biosciences position peaked at $74.7K in Q2 2025.
  • 18 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Riverview Capital Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.